Alpha Teknova, Inc. (TKNO)
USD 6.52
(-1.36%)
USD 6.52
(-1.36%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 38.55 Million USD | -26.4% |
| 2022 | 52.37 Million USD | 124.71% |
| 2021 | 23.3 Million USD | -49.49% |
| 2020 | 46.14 Million USD | 1.19% |
| 2019 | 45.6 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 36.42 Million USD | -2.71% |
| 2024 Q1 | 37.43 Million USD | -2.88% |
| 2023 Q1 | 48.93 Million USD | -6.57% |
| 2023 Q3 | 38.73 Million USD | -16.42% |
| 2023 FY | 38.55 Million USD | -26.4% |
| 2023 Q2 | 46.34 Million USD | -5.3% |
| 2023 Q4 | 38.55 Million USD | -0.47% |
| 2022 Q3 | 48.27 Million USD | -0.93% |
| 2022 FY | 52.37 Million USD | 124.71% |
| 2022 Q4 | 52.37 Million USD | 8.49% |
| 2022 Q2 | 48.72 Million USD | 7.01% |
| 2022 Q1 | 45.53 Million USD | 95.37% |
| 2021 FY | 23.3 Million USD | -49.49% |
| 2021 Q3 | 22.93 Million USD | -2.52% |
| 2021 Q2 | 23.53 Million USD | -60.67% |
| 2021 Q1 | 59.83 Million USD | 29.66% |
| 2021 Q4 | 23.3 Million USD | 1.62% |
| 2020 Q4 | 46.14 Million USD | 0.0% |
| 2020 Q1 | - USD | 0.0% |
| 2020 FY | 46.14 Million USD | 1.19% |
| 2019 FY | 45.6 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 471.67 Million USD | 91.827% |
| Aquestive Therapeutics, Inc. | 163.9 Million USD | 76.48% |
| Collegium Pharmaceutical, Inc. | 947.87 Million USD | 95.933% |
| Cosmos Health Inc. | 30.25 Million USD | -27.431% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -354.047% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 94.166% |
| Cronos Group Inc. | 43.73 Million USD | 11.855% |
| Incannex Healthcare Limited | 5.83 Million USD | -561.252% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | 20.423% |
| Lifecore Biomedical, Inc. | 219.8 Million USD | 82.461% |
| Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -17462.138% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -527.907% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -527.907% |
| SCYNEXIS, Inc. | 55.45 Million USD | 30.476% |
| Safety Shot Inc | 3.89 Million USD | -890.508% |
| Theratechnologies Inc. | 98.63 Million USD | 60.917% |
| Universe Pharmaceuticals INC | 13.75 Million USD | -180.283% |
| Pacira BioSciences, Inc. | 704.25 Million USD | 94.526% |
| Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | -340.281% |
| Dynavax Technologies Corporation | 375.02 Million USD | 89.72% |
| Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | 95.284% |
| Radius Health, Inc. | 804.29 Million USD | 95.207% |
| China SXT Pharmaceuticals, Inc. | 9.19 Million USD | -319.187% |
| Alvotech | 1.88 Billion USD | 97.952% |
| Intra-Cellular Therapies, Inc. | 136.87 Million USD | 71.834% |
| SIGA Technologies, Inc. | 57.97 Million USD | 33.507% |
| Shineco, Inc. | 47.6 Million USD | 19.013% |
| Silver Spike Investment Corp. | 3 Million USD | -1180.836% |
| Journey Medical Corporation | 56.49 Million USD | 31.767% |
| Petros Pharmaceuticals, Inc. | 21.31 Million USD | -80.857% |
| Embecta Corp. | 2.03 Billion USD | 98.107% |
| Harrow Health, Inc. | 241.75 Million USD | 84.054% |
| Procaps Group, S.A. | 462.06 Million USD | 91.657% |
| Biofrontera Inc. | 23.13 Million USD | -66.606% |
| DURECT Corporation | 30.4 Million USD | -26.787% |
| PainReform Ltd. | 2.69 Million USD | -1332.59% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 92.091% |
| OptiNose, Inc. | 194.33 Million USD | 80.163% |
| RedHill Biopharma Ltd. | 20.97 Million USD | -83.768% |
| Organogenesis Holdings Inc. | 181.36 Million USD | 78.744% |
| Cumberland Pharmaceuticals Inc. | 52.51 Million USD | 26.592% |
| ProPhase Labs, Inc. | 42.54 Million USD | 9.386% |
| Phibro Animal Health Corporation | 725.54 Million USD | 94.687% |
| Procaps Group S.A. | 462.06 Million USD | 91.657% |
| TherapeuticsMD, Inc. | 14.02 Million USD | -174.932% |
| Viatris Inc. | 27.21 Billion USD | 99.858% |
| Rockwell Medical, Inc. | 30.88 Million USD | -24.833% |
| Aytu BioPharma, Inc. | 90.37 Million USD | 57.345% |
| Tilray Brands, Inc. | 892.11 Million USD | 95.679% |
| PetIQ, Inc. | 645.22 Million USD | 94.025% |
| Talphera, Inc. | 6.29 Million USD | -512.893% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 96.218% |
| Alimera Sciences, Inc. | 107.35 Million USD | 64.09% |
| Assertio Holdings, Inc. | 148.41 Million USD | 74.025% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -1933.318% |
| Avadel Pharmaceuticals plc | 173.38 Million USD | 77.766% |
| Hempacco Co., Inc. | 18.82 Million USD | -104.814% |
| Alvotech | 1.88 Billion USD | 97.952% |
| Lantheus Holdings, Inc. | 835.25 Million USD | 95.385% |
| Kamada Ltd. | 109.96 Million USD | 64.944% |
| Currenc Group, Inc. | 177.67 Million USD | 78.303% |
| Indivior PLC | 1.95 Billion USD | 98.024% |
| Evoke Pharma, Inc. | 9.64 Million USD | -299.572% |
| Flora Growth Corp. | 17.22 Million USD | -123.847% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -354.047% |
| Evolus, Inc. | 209.68 Million USD | 81.615% |
| HUTCHMED (China) Limited | 536.38 Million USD | 92.813% |
| Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | 95.587% |
| Akanda Corp. | 12.66 Million USD | -204.297% |